



# AIM ImmunoTech Inc.

Q4 about inline. Announces positive data for 2 studies. Additional data expected to be strong catalysts for stock over the next year. Lowering P/T to \$8.00.

United States  
Healthcare

April 12, 2022

Edward Woo, CFA  
(949) 259-4932  
ewoo@ascendant.com

## COMPANY UPDATE

Rating: **BUY**

Ticker: AIM

Price: \$1.27

Target: \$8.00  
(from \$8.75)

**Q4 about inline:** AIM recently (on March 31) reported its Q4 2021 (ending December) results. Net loss was \$5.8 million or EPS of \$(0.12), compared with our and consensus estimates of \$(0.08) – (0.09). There was no guidance. AIM is an early/clinical stage drug development/commercialization company so it generates minimal revenue.

**Q4 update:** Pro forma operating expenses were \$5.5 million, up from \$3.8 million in Q3 2021 as the company ramps up clinical trial and research activities.

**No guidance:** Management did not provide forward guidance but we believe ~\$4 million is a reasonable near term quarterly cash burn rate.

**Adjusting estimates:** We are adjusting our 2022 EPS estimate to \$(0.37) from \$(0.35).

**Announces positive data from 2 studies:** AIM just announced positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM’s drug candidate, Ampligen. AIM also announced positive data from a Phase 2a study (also at Roswell Park) evaluating Ampligen as a component of a chemokine modulatory (CKM) regimen for the treatment of colorectal cancer metastatic to the liver.

**Potential COVID-19 treatment:** The extent (spread and effect) of the global pandemic of the new coronavirus (2019-nCoV) and COVID-19 has exploded globally (since early 2020) and even with vaccines widely used, it is still spreading due to new and changing variants (i.e. Delta and Omicron).

**Numerous COVID-19 studies underway:** The company is planning a major Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza. The goal is to establish Ampligen’s potential as a broad spectrum prophylaxis for respiratory viruses, including SARS-CoV-2. There are also various other COVID-19 studies planned or underway currently (in the U.S. and international).

**Ramp up in clinical trials:** In collaboration with major cancer research centers in the U.S., clinical trials are underway to test that the combination of Ampligen with checkpoint blockade therapies will improve clinical tumor responses, time to progression, and survival rates. There are seven cancer clinical trials underway or planned at the University of Pittsburgh Medical Center and Roswell Park Comprehensive Cancer Center.

**Clinical data can be catalyst:** AIM anticipates receiving additional clinical data from its various trials over the next year. Initial and recent data has been positive and further strong positive data will likely be catalysts for the stock.

**Positive high risks versus rewards:** We acknowledge that AIM’s oncology drugs still have long development roads left (~3 years), but we believe the ~billion dollars market potentials presents a high reward for the risks. In addition, the COVID-19 opportunities may be significant (and quicker to market).

**Current valuation attractive:** We are maintaining our BUY rating, but lowering our 12-month price target to \$8.00 from \$8.75, which is based on a NPV analysis. We believe this valuation appropriately balances out the company’s high risks with its high growth prospects and large upside opportunities.

### Company Description

Based in Ocala, FL, AIM ImmunoTech is a biotech company engaged in the clinical development of new drug therapies for the treatment of viral, immune, and immuno-oncology based diseases.

### Stock Data

Exchange:	NYSE
52-week Range:	\$0.55 – 2.40
Shares Outstanding (million):	48
Market cap (\$million):	\$61
EV (\$million):	\$13
Debt (\$million):	\$0
Cash (\$million):	\$48
Avg. Daily Trading Vol. (\$million):	\$1
Float (million shares):	47
Short Interest (million shares):	1
Dividend, annual (yield):	\$0 (NA%)

### Revenues (US\$ million)

	<u>2022E</u> <u>(Cur.)</u>	<u>2022E</u> <u>(Old)</u>	<u>2023E</u> <u>(Cur.)</u>	<u>2023E</u> <u>(Old)</u>
Q1 Mar	0.1E		0.1E	
Q2 Jun	0.0E		0.0E	
Q3 Sep	0.0E	0.1E	0.0E	
Q4 Dec	<u>0.1E</u>		<u>0.1E</u>	
Total	<b>0.2E</b>	<b>0.3E</b>	<b>0.2E</b>	
EV/Revs	N/A		N/A	

### Earnings per Share (pro forma)

	<u>2022E</u> <u>(Cur.)</u>	<u>2022E</u> <u>(Old)</u>	<u>2023E</u> <u>(Cur.)</u>	<u>2023E</u> <u>(Old)</u>
Q1 Mar	(0.09)E		(0.09)E	
Q2 Jun	(0.09)E		(0.09)E	
Q3 Sep	(0.09)E		(0.09)E	
Q4 Dec	<u>(0.09)E</u>		<u>(0.09)E</u>	
Total	<b>(0.37)E</b>	<b>(0.35)E</b>	<b>(0.35)E</b>	
P/E	N/A		N/A	

### Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

**For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 11.**

---

Exhibit 1: AIM ImmunoTech's Overview

## Investor Highlights

We are an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders

Lead program Ampligen® is an immuno-modulator with broad spectrum activity potentially applicable in multiple high-value indications

Multiple oncology clinical programs with upcoming clinical and regulatory milestones

Antiviral studies, including COVID-19, either underway or in development

Only late-stage program in development in the U.S. for the treatment of ME/CFS, with an approval in Argentina

## Investment Summary

**Immuno-Pharma Company with Broad Pipeline Across Multiple High-Value Indications in Oncology, Virology and Immune-Deficiency**

Lead program Ampligen® has favorable safety profile and promising efficacy

Leveraging external collaborators to fund ongoing clinical studies

Growing body of data potentially supports development strategy

**Strong Balance Sheet**

**Multiple Potentially Game-Changing Clinical and Regulatory Milestones Both Achieved and Expected Throughout 2022**

Source: Company reports

**Exhibit 2: Company Development Pipeline**

## Broad Oncology Pipeline Across High-Value Indications

Indications	Approach	Partner	Preclinical	Phase 1	Phase 2	Phase 3	Approval
Ovarian Cancer (Advanced, Recurrent)	Chemokine Modulatory Regimen	UPMC	[Progress Bar]				
Colorectal Cancer (Metastatic)	Chemokine Modulatory Regimen	ROSWELL PARK	[Progress Bar]				
Breast Cancer (Metastatic Triple-Negative)	Chemokine Modulatory Regimen / Pembrolizumab	ROSWELL PARK	[Progress Bar]				
Ovarian Cancer (Advanced, Recurrent)	Combination: Pembrolizumab	UPMC	[Progress Bar]				
Prostate Cancer (Early-Stage)	Combination: Intron A	ROSWELL PARK	[Progress Bar]				
Pancreatic Cancer	Single Agent	Erasmus MC	Early Access Program				
Breast Cancer (Early-Stage Triple- Negative)	Chemokine Modulatory Plus Neoadjuvant Chemo	ROSWELL PARK	[Progress Bar]				
Pancreatic Cancer	Ampligen Plus Checkpoint Inhibitor	University of Nebraska Medical Center	[Progress Bar]				
Melanoma	Single Agent	AIM ImmunoTech	[Progress Bar]				

## Extensive Viral and Immune System Disorder Pipeline

Indications	Approach	Preclinical	Phase 1	Phase 2	Phase 3	Approval
<b>Viral Infections</b>						
COVID-19 in Cancer Patients	Combination: Interferon Alpha-2b and Ampligen®	[Progress Bar]				
<b>Immune System Disorder</b>						
Severe CFS	Single Agent	[Progress Bar]				Approved in Argentina
ME/CFS	Single Agent	[Progress Bar]				Planning Phase 3 Confirmatory Trial
Long COVID-19	Single Agent	IND Planning Underway		Treating Patients in FDA Authorized Compassionate Care Program		

Source: Company reports.

### Exhibit 3: Ampligen Market Opportunity

## Lead Program Ampligen® (rintatolimod) Significant Opportunity Across Multiple Disease Areas

Generally well-tolerated with over 100,000 IV doses in humans

Clinically tested in oncology as a single-agent therapeutic and in combination with other agents

Potential in oncology to enhance efficacy of PD-1 and PD-L1 checkpoint inhibitors<sup>1</sup>

Phase 3 in ME/CFS completed in U.S. – NDA filing pending confirmatory Phase 3 following complete response letter; Approved for the treatment of severe CFS in Argentina

Immuno-Oncology

Virology

Immune System Disorders

## Ampligen® May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19)

Targeting toll-like receptor 3 (TLR3) pathways, which are among the primary pathways for antiviral protection (uniquely targets TLR3 without activation of the inflammatory cytosolic helicases)

Potential efficacy may not be impacted by viral mutations, such as Delta, Omicron or future given mechanism of action

Demonstrated complete protection (100% survival) against SARS-CoV-1, Ebola virus disease, and Western Equine Encephalitis virus in preclinical studies

Identified an effective *in vitro* model using human tracheal, bronchial epithelial cells, which showed that Ampligen® was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen® dosage levels

## Ampligen® for the Treatment of ME/CFS

Only late-stage program in development in the U.S. for the treatment of ME/CFS, with an approval in Argentina



Developing protocol for confirmatory Phase 3 trial, required for U.S. NDA

Toll-Like Receptor 3 agonist which activates the innate immune system and induces immuno-modulation

Source: Company reports.

---

## Exhibit 4: Ongoing Ampligen Cancer Clinical Studies

### Immuno-Therapy Targeting Multiple Cancers with High Unmet Need

- Advanced Recurrent Ovarian Cancer – Phase 1 portion was completed. A follow-up Phase 2 study of advanced recurrent ovarian cancer using cisplatin and pembrolizumab, plus Ampligen; up to 45 patients to be enrolled; numerous patients have commenced treatment. [ClinicalTrials.gov: NCT03734692](#)
- Stage 4 Colorectal Cancer Metastatic to the Liver – Phase 2a study of Ampligen as a component of a chemokine modulatory regimen on colorectal cancer metastatic to liver has been completed; 15 patients were enrolled and treated. Data was accepted for a late-breaking presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13, 2022 and are under embargo until then. [ClinicalTrials.gov: NCT03403634](#)
- Stage 4 Metastatic Triple Negative Breast Cancer – Phase 1/2 study of metastatic triple-negative breast cancer using chemokine modulation therapy, including Ampligen and pembrolizumab. Eight patients were enrolled and treated. Data was accepted for a late-breaking presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13, 2022 and are under embargo until then. [ClinicalTrials.gov: NCT03599453](#)
- Early-Stage Prostate Cancer – Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy. Patient enrollment has been initiated in this study designed for up to 45 patients. [ClinicalTrials.gov: NCT03899987](#)
- Early-Stage Triple Negative Breast Cancer – Phase 1 study of chemokine modulation plus neoadjuvant chemotherapy in patients with early-stage triple negative breast cancer has received FDA authorization. The objective of this study is to evaluate the safety and tolerability of a combination of Ampligen and celecoxib with or without Intron A, when given along with chemotherapy. The goal of this approach is to increase survival. This study is recruiting patients and is designed for up to 24 patients. [ClinicalTrials.gov: NCT04081389](#)
- Refractory Melanoma – Phase 2 study that will evaluate polarized dendritic cell vaccine, interferon alpha-2, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma at Roswell Park. Up to 24 patients to be enrolled. [ClinicalTrials.gov: NCT04093323](#)
- Advanced Ovarian Cancer – AIM plans to develop a Phase 2 Cisplatin Resistant Advanced Recurrent Ovarian Cancer Clinical Study utilizing Ampligen at the University of Pittsburgh.

Source: Company reports.

---

## Exhibit 5: Ampligen for COVID-19 and ME/CFS

### Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19)

Previous animal studies yielded positive results utilizing Ampligen to treat Western Equine Encephalitis Virus, Ebola and SARS-CoV-1. The Company has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication. The prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against SARS-CoV-2. AIM is currently evaluating the safety and effectiveness of intravenous Ampligen to reduce replication of SARS-CoV-2 virus from upper airway in patients in an ongoing Phase 1/2 study for the treatment of COVID-19 cancer patients. The Company plans to conduct an intranasal study of Ampligen to potentially enhance and expand natural immunity.

### Immune System Disorders (ISD): Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) / COVID-19 Long Hauler

The Company is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the United States, and in 2021 AIM dosed its first "Long Hauler" patient with Ampligen in its post-COVID-19 "Long Hauler" portion of the active AMP-511 EAP in the United States. Early data from the ongoing AMP-511 EAP and data from an earlier study, AMP-502, has indicated that patients with cognitive function deficiency have reported improvements in cognitive function after Ampligen treatment.

Source: Company reports.

## Exhibit 6: AIM Upcoming Milestones

Q1 2022	Q2 2022	Q3 2022	Q4 2022
<p><b>Oncology</b></p> <ul style="list-style-type: none"> <li>✓ January 2022: Advanced Recurrent Ovarian Cancer: Phase 1 Publication of Results</li> <li>✓ March: Late-Stage Pancreatic Cancer: EAP Publications of Results</li> <li>✓ March 2022: Advanced Recurrent Ovarian Cancer: Phase 2 Interim Results</li> <li>✓ March 2022: FDA IND clearance of Phase 2 Locally advanced Pancreatic Cancer study</li> </ul>	<p><b>Oncology</b></p> <ul style="list-style-type: none"> <li>• Pancreatic Cancer Expressing TLR3 Receptors: Publication of Preclinical Data</li> <li>• Metastatic Triple-Negative Breast Cancer: Phase 1/2 Results</li> <li>• Colorectal Cancer Metastatic to Liver: Phase 2a Results</li> </ul>	<p><b>Immune System Disorders</b></p> <ul style="list-style-type: none"> <li>• Report Interim Results from AMP-511 COVID19 and Progress from Planned Post-COVID Phase 1/2</li> </ul>	<p><b>Oncology</b></p> <ul style="list-style-type: none"> <li>• Locally Advanced Pancreatic Cancer: Launch Phase 2 Study</li> </ul>
		<p><b>Antiviral</b></p> <ul style="list-style-type: none"> <li>• COVID-19 in Cancer Patients: Phase 1/2 Interim Results</li> </ul>	

Source: Company reports.

**Exhibit 7: AIM ImmunoTech Stock Price (Five Years)**



Source: <https://bigcharts.marketwatch.com/>

**Exhibit 8: Consensus Expectations (as of March 31, 2022)**

	Revenue (mil)			EPS	
	2021E	2022E		2021E	2022E
Q1 Mar	\$0.0A	\$0.7E	Q1 Mar	\$(0.08)A	\$(0.07)E
Q2 Jun	\$0.0A		Q2 Jun	\$(0.12)A	
Q3 Sep	\$0.0A		Q3 Sep	\$(0.08)A	
Q4 Dec	\$0.0E		Q4 Dec	\$(0.09)E	
<b>Total</b>	<b>\$0.1E</b>	<b>\$1.9E</b>	<b>Total</b>	<b>\$(0.38)E</b>	<b>\$(0.29)E</b>

\*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, Refinitiv, and Ascendant Capital Markets estimates

## FINANCIAL MODEL

### AIM ImmunoTech Inc.

Income Statement (\$ mils)	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E	
<b>Total Revenue</b>	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.1	0.1	0.2
Cost of Revenues	0.2	0.2	0.2	0.2	0.8	0.2	0.3	0.2	0.2	0.9	0.1	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.1	0.4
Gross Profit	(0.2)	(0.2)	(0.2)	(0.2)	(0.6)	(0.2)	(0.3)	(0.1)	(0.1)	(0.7)	(0.1)	(0.0)	(0.0)	(0.1)	(0.2)	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.2)
Research and development	0.9	1.5	1.1	2.3	5.7	1.4	1.3	2.0	2.9	7.7	2.2	2.2	2.2	2.2	8.8	2.0	2.0	2.0	2.0	2.0	8.0
General and administrative	2.3	1.7	2.1	2.6	8.7	2.1	2.1	1.8	2.6	8.7	2.2	2.2	2.2	2.2	8.8	2.2	2.2	2.2	2.2	2.2	8.8
Restructuring and other				0.1	0.1				1.8	1.8					0.0						0.0
Total operating expenses	3.2	3.2	3.2	5.0	14.5	3.5	3.5	3.8	7.3	18.1	4.4	4.4	4.4	4.4	17.6	4.2	4.2	4.2	4.2	4.2	16.8
<b>Operating income (loss)</b>	(3.3)	(3.3)	(3.4)	(5.1)	(15.2)	(3.7)	(3.7)	(3.9)	(7.4)	(18.8)	(4.5)	(4.4)	(4.4)	(4.5)	(17.8)	(4.3)	(4.2)	(4.2)	(4.3)	(4.3)	(17.0)
Interest income (expense)	(0.3)	(0.2)	0.0	0.0	(0.5)	0.0	0.0	(0.0)	(0.1)	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)	(0.2)	0.2	0.0	1.2	1.2	0.1	(2.2)	0.1	1.7	(0.2)											
Income before income taxes	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(4.5)	(4.4)	(4.4)	(4.5)	(17.8)	(4.3)	(4.2)	(4.2)	(4.3)	(4.3)	(17.0)
Income taxes					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(4.5)	(4.4)	(4.4)	(4.5)	(17.8)	(4.3)	(4.2)	(4.2)	(4.3)	(4.3)	(17.0)
Nonrecurring/noncash adjustments					0.0					0.0					0.0						0.0
<b>Net income (pro forma)</b>	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(4.5)	(4.4)	(4.4)	(4.5)	(17.8)	(4.3)	(4.2)	(4.2)	(4.3)	(4.3)	(17.0)
EBITDA																					
Shares, Basic	17.5	30.0	38.9	41.0	31.8	45.7	47.8	47.8	47.8	47.3	48.1	48.2	48.3	48.4	48.3	48.5	48.6	48.7	48.8	48.8	48.7
Shares, Diluted	17.5	30.0	38.9	41.0	31.8	45.7	47.8	47.8	47.8	47.3	48.1	48.2	48.3	48.4	48.3	48.5	48.6	48.7	48.8	48.8	48.7
EPS Basic (Pro forma)	(\$0.22)	(\$0.11)	(\$0.08)	(\$0.10)	(\$0.45)	(\$0.08)	(\$0.12)	(\$0.08)	(\$0.12)	(\$0.40)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.37)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.35)
EPS Diluted (Pro forma)	(\$0.22)	(\$0.11)	(\$0.08)	(\$0.10)	(\$0.45)	(\$0.08)	(\$0.12)	(\$0.08)	(\$0.12)	(\$0.40)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.37)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.09)	(\$0.35)
<b>Margins</b>																					
Gross margin	-353%	-400%	-467%	-371%	-394%	-746%	-1113%	-376%	-247%	-530%	-100%	-100%	-100%	-100%	-100%	-100%	-100%	-100%	-100%	-100%	-100%
Research and development	1996%	3658%	3061%	5374%	3509%	5086%	5726%	6079%	5735%	5683%	3929%	4783%	6061%	3922%	4527%	3571%	4348%	5510%	3565%	4115%	4527%
General and administrative	5040%	4293%	5792%	6152%	5309%	7543%	9326%	5452%	5129%	6424%	3929%	4783%	6061%	3922%	4527%	3929%	4783%	6061%	3922%	4527%	4527%
Operating margin	-7389%	-8350%	-9319%	#####	-9296%	-13375%	-16165%	-11906%	#####	-13954%	-7957%	-9665%	#####	-7943%	-9153%	-7600%	-9230%	#####	-7587%	-8742%	-8742%
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	-8462%	-8425%	-9183%	-9324%	-8834%	-12782%	-25548%	-11594%	#####	-14168%	-7957%	-9665%	#####	-7943%	-9153%	-7600%	-9230%	#####	-7587%	-8742%	-8742%
<b>Y/Y % change</b>																					
Total Revenue	#DIV/0!	38%	-41%	-16%	16%	-38%	-43%	-8%	21%	-17%	100%	100%	10%	10%	44%	0%	0%	0%	0%	0%	0%
Gross margin	-31%	-14%	-1%	-7%	-15%	31%	60%	-26%	-19%	11%	-73%	-82%	-71%	-55%	-73%	0%	0%	0%	0%	0%	0%
Research and development	-3%	33%	-7%	57%	23%	59%	-10%	82%	30%	34%	54%	67%	10%	-25%	15%	-9%	-9%	-9%	-9%	-9%	-9%
General and administrative	28%	-12%	13%	74%	23%	-7%	25%	-14%	1%	0%	4%	3%	22%	-16%	1%	0%	0%	0%	0%	0%	0%
Operating income (loss)	14%	4%	5%	66%	22%	13%	11%	17%	45%	24%	19%	20%	13%	-40%	-6%	-4%	-4%	-5%	-4%	-4%	-4%
Net income (loss)	13%	66%	12%	230%	51%	-6%	74%	16%	49%	33%	25%	-24%	16%	-24%	-7%	-4%	-4%	-5%	-4%	-4%	-4%
EPS Diluted (Pro forma)	-93%	-89%	-92%	-28%	-83%	-64%	9%	-6%	28%	-11%	18%	-25%	15%	-25%	-9%	-5%	-5%	-5%	-5%	-5%	-5%

Source: Company reports and Ascendant Immune stock split in June 2019



**AIM ImmunoTech Inc.**

Balance Sheet (\$ mils)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
<b>Assets</b>																
Cash and cash equivalents	27.6	33.9	38.5	38.5	48.8	41.1	37.3	32.1	31.8	27.4	22.8	20.0	18.1	13.8	9.4	5.3
Short term investments	0.5	1.1	1.1	0.5	1.2		0.5	16.2	16.2	16.2	16.2	16.2	16.2	16.2	16.2	16.2
Accounts receivable, net	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income taxes									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	1.6	0.1	0.1	1.3	1.2	0.2	0.2	1.9	0.3	0.2	0.2	0.3	0.3	0.2	0.2	0.3
<b>Total current assets</b>	<b>29.7</b>	<b>35.2</b>	<b>39.8</b>	<b>40.3</b>	<b>51.2</b>	<b>41.3</b>	<b>38.0</b>	<b>50.2</b>	<b>48.3</b>	<b>43.8</b>	<b>39.1</b>	<b>36.5</b>	<b>34.6</b>	<b>30.2</b>	<b>25.7</b>	<b>21.8</b>
Long term securities/investments	3.0	5.3	14.8	15.4	13.7	16.1	15.8		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property and equipment, net	7.0	6.8	6.6	6.5	6.3	6.1	6.0	4.0	3.9	3.7	3.3	3.2	2.8	2.6	2.3	1.9
Intangibles, net	1.2	1.4	1.4	1.5	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Deferred income tax									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	1.5	1.5	1.5	0.9	1.1	1.3	1.4	1.5	1.5	1.5	1.5	0.0	0.0	0.0	0.0	0.0
<b>Total assets</b>	<b>42.4</b>	<b>50.1</b>	<b>64.2</b>	<b>64.6</b>	<b>74.1</b>	<b>66.7</b>	<b>63.1</b>	<b>57.7</b>	<b>55.7</b>	<b>51.0</b>	<b>45.9</b>	<b>41.6</b>	<b>39.3</b>	<b>34.8</b>	<b>30.0</b>	<b>25.6</b>
<b>Liabilities and stockholders' equity</b>																
Accounts payable	0.2	0.3	0.2	0.4	0.2	0.5	0.4	0.2	1.1	0.9	0.7	0.6	1.1	0.9	0.7	0.6
Accrued expenses	0.3	0.3	0.3	0.4	0.5	0.4	0.4	0.4	1.7	1.4	0.7	0.6	1.7	1.4	0.7	0.6
Accrued interest									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.3	0.3
Short term debt	0.2	0.2	0.2	0.2	0.2				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total current liabilities</b>	<b>0.7</b>	<b>0.8</b>	<b>0.8</b>	<b>1.1</b>	<b>1.0</b>	<b>0.9</b>	<b>0.8</b>	<b>0.7</b>	<b>2.8</b>	<b>2.3</b>	<b>1.5</b>	<b>1.4</b>	<b>3.1</b>	<b>2.6</b>	<b>1.8</b>	<b>1.4</b>
Deferred income taxes									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Long term debt	6.2	2.0	1.9	1.9	1.8				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total other liabilities</b>	<b>6.6</b>	<b>2.3</b>	<b>2.3</b>	<b>2.2</b>	<b>2.2</b>	<b>0.3</b>	<b>0.3</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>	<b>0.1</b>
Preferred stock	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.8	1.0	1.3	1.5	1.8	2.0
Additional paid-in capital	366.2	381.4	398.9	402.5	416.0	416.4	416.8	417.2	417.2	417.2	417.2	417.2	417.2	417.2	417.2	417.2
Retained earnings	(331.9)	(335.3)	(338.6)	(342.0)	(345.6)	(351.4)	(355.3)	(361.1)	(365.6)	(370.0)	(374.4)	(378.9)	(383.2)	(387.4)	(391.6)	(395.9)
Treasury stock									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accumulated other comprehensive income	(0.0)	0.1	(0.0)	(0.0)	(0.2)	(0.2)	(0.3)		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total stockholders' equity</b>	<b>35.1</b>	<b>47.0</b>	<b>61.1</b>	<b>61.3</b>	<b>71.0</b>	<b>65.5</b>	<b>62.0</b>	<b>56.9</b>	<b>52.7</b>	<b>48.5</b>	<b>44.3</b>	<b>40.1</b>	<b>36.1</b>	<b>32.1</b>	<b>28.1</b>	<b>24.1</b>
<b>Total stockholders' equity and liabilities</b>	<b>42.4</b>	<b>50.1</b>	<b>64.2</b>	<b>64.6</b>	<b>74.1</b>	<b>66.7</b>	<b>63.1</b>	<b>57.7</b>	<b>55.7</b>	<b>51.0</b>	<b>45.9</b>	<b>41.6</b>	<b>39.3</b>	<b>34.8</b>	<b>30.0</b>	<b>25.6</b>

**Balance Sheet Drivers**

	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Prepaid as % of total rev	3500%	295%	253%	3033%	4457%	674%	488%	3814%	500%	500%	500%	500%	500%	500%	500%	500%
Accounts payable as % of total rev	367%	638%	569%	912%	675%	1961%	1118%	388%	2000%	2000%	2000%	1000%	2000%	2000%	2000%	1000%
Inventories as % of cost of rev	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Accrued expenses as % of total rev	636%	813%	894%	1052%	1779%	1622%	1097%	859%	3000%	3000%	2000%	1000%	3000%	3000%	2000%	1000%
<b>Activity Ratios</b>																
A/R Days Sales Outstanding	92	104	65	73	109	110	76	0	70	70	70	70	70	70	70	70
Inventory Turnover	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
A/P Days Payable	73	115	90	174	72	145	212	101	900	900	900	450	900	900	900	450
<b>Book &amp; Cash Value (per share)</b>																
Book Value per Share (diluted)	\$2.01	\$1.57	\$1.57	\$1.49	\$1.55	\$1.37	\$1.30	\$1.19	\$1.10	\$1.01	\$0.92	\$0.83	\$0.74	\$0.66	\$0.58	\$0.49
Cash per Share (diluted)	\$1.78	\$1.34	\$1.40	\$1.33	\$1.39	\$1.20	\$1.12	\$1.01	\$1.00	\$0.90	\$0.81	\$0.75	\$0.71	\$0.62	\$0.52	\$0.44
Net cash per Share (diluted)	\$1.41	\$1.27	\$1.34	\$1.27	\$1.35	\$1.20	\$1.12	\$1.01	\$1.00	\$0.90	\$0.81	\$0.75	\$0.71	\$0.62	\$0.52	\$0.44

Source: Company reports and Ascendant Capital Markets estimates

**AIM ImmunoTech Inc.**

Cash Flow Statement (\$ mils)	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
<b>Cash flow from operating activities</b>																				
Net income	(3.8)	(3.4)	(3.3)	(3.9)	(14.4)	(3.6)	(5.9)	(3.8)	(5.8)	(19.1)	(4.5)	(4.4)	(4.4)	(4.5)	(17.8)	(4.3)	(4.2)	(4.2)	(4.3)	(17.0)
Depreciation	0.2	0.2	0.2	0.2	0.7	0.2	0.2	0.2	0.2	0.7	0.2	0.2	0.2	0.2	0.7	0.2	0.2	0.2	0.2	0.7
Amortization	0.2	(0.1)	(0.0)	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Debt related amortization exper	0.2	(0.1)	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Stock comp	0.2	0.1	0.3	0.4	1.0	0.5	0.5	0.3	0.2	1.6	0.2	0.2	0.2	0.2	1.0	0.2	0.2	0.2	0.2	1.0
Deferred income taxes					0.0	(0.2)	0.2	(0.5)	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Provision for bad debts				(0.0)	(0.0)					0.0					0.0					0.0
Reserves					0.0					0.0					0.0					0.0
Change in fair value of warrant I	0.2	(0.0)	(0.0)	(0.0)	0.1	0.0	(0.0)	(0.1)	(0.1)	(0.1)					0.0					0.0
Writedowns and impairments				1.4	1.4				1.8	1.8					0.0					0.0
Other gains/losses	(0.0)	0.2	(0.1)	(0.1)	0.0		2.0	0.6	(2.4)	0.2				0.0						0.0
Other		0.0	(0.1)	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0				0.0						0.0
<b>Changes in operating assets and liabilities:</b>																				
Accounts receivable	(0.0)	0.8	0.0	(0.8)	0.0		0.0		0.0	0.0	(0.0)	0.0	0.0	(0.0)	(0.0)	0.0	0.0	0.0	0.0	(0.0)
Inventory					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses & other curre	0.0	0.7	0.1	(0.1)	0.7	0.0	0.0	(0.0)	1.6	1.6	1.7	0.1	0.0	(0.1)	1.7	0.0	0.1	0.0	0.0	(0.1)
Income tax				(0.3)	(0.3)			1.1	(1.1)	0.0					0.0					0.0
Other assets	(0.0)	(0.0)	(0.2)	0.3	0.0	(0.0)	(0.0)	(0.0)	(0.5)	(0.6)	0.0	0.0	0.0	1.5	1.5	0.0	0.0	0.0	0.0	0.0
Accounts payable	(0.3)	0.1	0.4	(0.3)	(0.1)	(0.2)	0.3	(0.1)	(0.2)	(0.2)	0.9	(0.2)	(0.2)	(0.2)	0.4	0.6	(0.2)	(0.2)	(0.2)	0.0
Accrued expenses	(0.1)	0.0	(0.2)	0.4	0.0	0.1	(0.1)	(0.0)	0.1	(0.0)	1.2	(0.3)	(0.7)	(0.2)	0.1	1.1	(0.3)	(0.7)	(0.2)	0.0
Accrued interest	0.1	0.1			0.2					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities					0.0					0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0
<b>Net cash (used in) provided by</b>	<b>(3.1)</b>	<b>(1.5)</b>	<b>(3.0)</b>	<b>(2.9)</b>	<b>(10.4)</b>	<b>(3.0)</b>	<b>(1.7)</b>	<b>(3.5)</b>	<b>(5.7)</b>	<b>(14.0)</b>	<b>(0.2)</b>	<b>(4.5)</b>	<b>(4.8)</b>	<b>(2.7)</b>	<b>(12.3)</b>	<b>(2.2)</b>	<b>(4.3)</b>	<b>(4.6)</b>	<b>(4.3)</b>	<b>(15.3)</b>
<b>Cash flow from investing activities</b>																				
Purchases of property and equi	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)		0.2	(0.0)	(0.0)	0.2	(0.0)	(0.0)	0.2	(0.0)	0.2	0.2	(0.0)	0.2	0.2	0.6
Purchases of short-term investn	3.8	(2.9)	(9.6)	0.1	(8.6)	0.9	(1.4)	(0.3)	0.5	(0.2)					0.0					0.0
Acquisitions	(0.3)			(0.3)	(0.6)	(0.4)		(0.1)	(0.1)	(0.6)					0.0					0.0
Other					0.0					0.0					0.0					0.0
<b>Net cash used in investing activ</b>	<b>3.5</b>	<b>(2.9)</b>	<b>(9.6)</b>	<b>(0.2)</b>	<b>(9.2)</b>	<b>0.5</b>	<b>(1.2)</b>	<b>(0.4)</b>	<b>0.4</b>	<b>(0.6)</b>	<b>(0.0)</b>	<b>(0.0)</b>	<b>0.2</b>	<b>(0.0)</b>	<b>0.2</b>	<b>0.2</b>	<b>(0.0)</b>	<b>0.2</b>	<b>0.2</b>	<b>0.6</b>
<b>Cash flow from financing activities</b>																				
Issuance of debt				(0.4)	(0.4)					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt	(0.1)	(4.4)	(0.1)	0.2	(4.3)	(0.1)	(4.8)	(0.0)	0.0	(4.9)					0.0					0.0
Issuance of stock	25.8	15.0	17.2	3.2	61.2	12.9		0.0	0.1	13.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repurchase of common stock					0.0					0.0					0.0					0.0
Proceeds from stock option exercises					0.0					0.0					0.0					0.0
Other					0.0					0.0					0.0					0.0
Dividends and distributions					0.0					0.0					0.0					0.0
<b>Cash provided by (used in) fina</b>	<b>25.7</b>	<b>10.7</b>	<b>17.2</b>	<b>3.0</b>	<b>56.6</b>	<b>12.8</b>	<b>(4.8)</b>	<b>0.0</b>	<b>0.1</b>	<b>8.2</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
Effect of exchange rate on cash					0.0					0.0					0.0					0.0
<b>Net increase (decrease) in cash</b>	<b>26.1</b>	<b>6.3</b>	<b>4.6</b>	<b>0.0</b>	<b>37.0</b>	<b>10.3</b>	<b>(7.6)</b>	<b>(3.8)</b>	<b>(5.3)</b>	<b>(6.4)</b>	<b>(0.3)</b>	<b>(4.5)</b>	<b>(4.6)</b>	<b>(2.8)</b>	<b>(12.1)</b>	<b>(2.0)</b>	<b>(4.3)</b>	<b>(4.4)</b>	<b>(4.1)</b>	<b>(14.7)</b>
<b>Beginning cash and equivalents</b>	<b>1.5</b>	<b>27.6</b>	<b>33.9</b>	<b>38.5</b>	<b>1.5</b>	<b>38.5</b>	<b>48.8</b>	<b>41.1</b>	<b>37.3</b>	<b>38.5</b>	<b>32.1</b>	<b>31.8</b>	<b>27.4</b>	<b>22.8</b>	<b>32.1</b>	<b>20.0</b>	<b>18.1</b>	<b>13.8</b>	<b>9.4</b>	<b>20.0</b>
<b>Ending cash and equivalents</b>	<b>27.6</b>	<b>33.9</b>	<b>38.5</b>	<b>38.5</b>	<b>38.5</b>	<b>48.8</b>	<b>41.1</b>	<b>37.3</b>	<b>32.1</b>	<b>32.1</b>	<b>31.8</b>	<b>27.4</b>	<b>22.8</b>	<b>20.0</b>	<b>20.0</b>	<b>18.1</b>	<b>13.8</b>	<b>9.4</b>	<b>5.3</b>	<b>5.3</b>

Source: Company reports and Ascendant Capital Markets estimates

## ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

## AIM ImmunoTech Inc.



Source: <https://bigcharts.marketwatch.com/>

	Report Date		Price
Report	Date	Rating	Target
1	10/29/2018	Buy	33.00
2	11/21/2018	Buy	30.80
3	4/2/2019	Buy	28.60
4	5/16/2019	Buy	26.40
5	8/21/2019	Buy	6.00
6	11/17/2019	Buy	2.50
7	1/26/2020	Buy	3.00
8	4/4/2020	Buy	6.00
9	5/24/2020	Buy	7.00
10	8/21/2020	Buy	7.25
11	11/28/2020	Buy	7.50
12	4/6/2021	Buy	7.75
13	5/21/2021	Buy	8.00
14	9/7/2021	Buy	8.50
15	11/28/2021	Buy	8.75

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

## IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

### Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

### Ascendant Capital Markets, LLC Rating System

**BUY:** We expect the stock to provide a total return of 15% or more within a 12-month period.

**HOLD:** We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

**SELL:** We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

### Ascendant Capital Markets, LLC Rating System

*Prior to January 31, 2014, ASCM used the following rating system:*

**Strong Buy:** We expect the stock to provide a total return of 30% or more within a 12-month period.

**Buy:** We expect the stock to provide a total return of between 10% and 30% within a 12-month period.

**Neutral:** We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.

**Sell:** We expect the stock to provide a total return of minus 10% or worse within a 12-month period.

**Speculative Buy:** This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.

### Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of January 15, 2022)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	40	98%	16	40%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	41	100%	16	39%

### Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

### Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

### General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

### Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.